IMPC phenotypes (gene matching)
- anophthalmia / IMPC
B6Rcc.129-Cd44tm1Ugu Spp1tm1Rit/Cnrm
| Status | Available to order |
| EMMA ID | EM:01991 |
| International strain name | B6Rcc.129-Cd44tm1Ugu Spp1tm1Rit/Cnrm |
| Alternative name | C57 BL/6RCC CD44v7-/- OPN-/- |
| Strain type | Targeted Mutant Strains : Knock-out |
| Allele/Transgene symbol | Cd44tm1Ugu, Spp1tm1Rit |
| Gene/Transgene symbol | Cd44, Spp1 |
Information from provider
| Provider | Ursula Günthert |
| Provider affiliation | Institut für Pathologie, University of Basel |
| Genetic information | A loxP site was inserted 3' of exon v6 and a neomycin resistance cassette, with a 5' loxP site, was inserted 5' of exon v6 of the Cd44 gene. During insertion, 1.6 kb of sequence was lost in the exon v7 region leading to deficient expression of this variant in homozygous mutant mice (Cd44v7 -/-). The neomycin cassette from pMC1neo was inserted into the EagI site in exon 6 of the Spp1 (secreted phosphoprotein 1; formerly: Opn, osteopontin) gene (a 4.8 kb fragment from 129 mice), that had been cloned into pBluescript (Rittling et al., 1998). |
| Phenotypic information | Cd44v7-/-: Strongly reduced symptoms in autoimmune diseases. Opn (Spp1)-/-: Strongly reduced symptoms in autoimmune diseases and impaired bone remodeling. |
| Breeding history | 10 generations backcrossed onto C57BL/6Rcc; currently bred as C57BL/6Rcc Cd44v7-/- Opn-/-. |
| References |
|
Information from EMMA
| Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
Disease and phenotype information
MGI phenotypes (allele matching)
- abnormal digestive system physiology / MGI
- immune system phenotype / MGI
- abnormal T-helper 1 physiology / MGI
- abnormal T-helper 2 physiology / MGI
- abnormal liver morphology / MGI
- decreased acute inflammation / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-gamma secretion / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- increased bone mineral density / MGI
- abnormal osteoclast physiology / MGI
- abnormal cardiovascular system physiology / MGI
- abnormal inflammatory response / MGI
- decreased susceptibility to viral infection / MGI
- dilated renal tubules / MGI
- decreased heart weight / MGI
- delayed wound healing / MGI
- nervous system phenotype / MGI
- abnormal physiological neovascularization / MGI
- renal tubular necrosis / MGI
- increased osteoclast cell number / MGI
- decreased osteoclast cell number / MGI
- decreased bone resorption / MGI
- abnormal osteoblast physiology / MGI
- abnormal response to infection / MGI
- decreased cardiac muscle contractility / MGI
- increased susceptibility to injury / MGI
- skeleton phenotype / MGI
- hyporesponsive to tactile stimuli / MGI
- increased circulating creatinine level / MGI
- increased blood urea nitrogen level / MGI
- decreased susceptibility to type IV hypersensitivity reaction / MGI
- increased interleukin-10 secretion / MGI
- decreased interleukin-12 secretion / MGI
- increased interleukin-4 secretion / MGI
- decreased sensitivity to induced cell death / MGI
- increased trabecular bone thickness / MGI
- mortality/aging / MGI
- decreased fibroblast chemotaxis / MGI
- increased bone marrow cell number / MGI
- abnormal blood cell morphology/development / MGI
- abnormal bone mineralization / MGI
- increased hematopoietic stem cell number / MGI
- increased sensitivity to induced morbidity/mortality / MGI
MGI phenotypes (gene matching)
- decreased mast cell number / MGI
- altered response to myocardial infarction / MGI
- abnormal cell morphology / MGI
- decreased mast cell histamine storage / MGI
- abnormal uterus morphology / MGI
- thin epidermis / MGI
- abnormal lipid level / MGI
- abnormal vasculogenesis / MGI
- abnormal digestive system physiology / MGI
- impaired wound healing / MGI
- impaired macrophage phagocytosis / MGI
- liver inflammation / MGI
- lung inflammation / MGI
- abnormal definitive hematopoiesis / MGI
- no abnormal phenotype detected / MGI
- abnormal CD4-positive, alpha beta T cell morphology / MGI
- abnormal neutrophil physiology / MGI
- short tibia / MGI
- impaired skin barrier function / MGI
- delayed wound healing / MGI
- decreased myocardial infarction size / MGI
- abnormal leukocyte migration / MGI
- peritoneal inflammation / MGI
- decreased susceptibility to induced arthritis / MGI
- decreased tumor growth/size / MGI
- abnormal leukocyte adhesion / MGI
- abnormal physiological neovascularization / MGI
- increased susceptibility to induced arthritis / MGI
- enhanced coordination / MGI
- decreased cholesterol level / MGI
- abnormal vascular endothelial cell physiology / MGI
- decreased susceptibility to kidney reperfusion injury / MGI
- abnormal miniature excitatory postsynaptic currents / MGI
- decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
- increased mean systemic arterial blood pressure / MGI
- abnormal CD8-positive, alpha beta T cell morphology / MGI
- abnormal response to infection / MGI
- increased susceptibility to parasitic infection / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- decreased acute inflammation / MGI
- increased acute inflammation / MGI
- decreased T cell proliferation / MGI
- digestive/alimentary phenotype / MGI
- immune system phenotype / MGI
- hematopoietic system phenotype / MGI
- abnormal CD4-positive, alpha-beta T cell physiology / MGI
- abnormal T-helper 1 physiology / MGI
- abnormal T-helper 2 physiology / MGI
- choroidal neovascularization / MGI
- decreased circulating creatinine level / MGI
- decreased blood urea nitrogen level / MGI
- abnormal vascular smooth muscle physiology / MGI
- decreased angiogenesis / MGI
- decreased susceptibility to type IV hypersensitivity reaction / MGI
- abnormal cell physiology / MGI
- abnormal vascular endothelial cell morphology / MGI
- abnormal involution of the mammary gland / MGI
- increased diameter of tibia / MGI
- abnormal osteoclast differentiation / MGI
- increased circulating tumor necrosis factor level / MGI
- decreased circulating tumor necrosis factor level / MGI
- increased tumor necrosis factor secretion / MGI
- abnormal interleukin secretion / MGI
- increased circulating interferon-gamma level / MGI
- increased circulating interleukin-2 level / MGI
- increased interleukin-1 beta secretion / MGI
- increased interleukin-10 secretion / MGI
- increased interleukin-6 secretion / MGI
- impaired neutrophil recruitment / MGI
- abnormal chemokine secretion / MGI
- decreased transforming growth factor level / MGI
- decreased sensitivity to induced cell death / MGI
- abnormal epidermal lamellar body morphology / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- abnormal circulating chemokine level / MGI
- abnormal circulating cytokine level / MGI
- decreased activation-induced cell death of T cells / MGI
- increased mitochondria size / MGI
- abnormal mitochondrial crista morphology / MGI
- decreased fibroblast proliferation / MGI
- impaired leukocyte tethering or rolling / MGI
- increased bone mineral density / MGI
- abnormal long bone metaphysis morphology / MGI
- abnormal microglial cell morphology / MGI
- decreased hematocrit / MGI
- decreased leukocyte cell number / MGI
- abnormal blood flow velocity / MGI
- abnormal blood vessel physiology / MGI
- increased bone marrow cell number / MGI
- altered response to myocardial infarction / MGI
- abnormal liver morphology / MGI
- abnormal substantia nigra morphology / MGI
- abnormal osteoclast physiology / MGI
- abnormal cardiovascular system physiology / MGI
- abnormal hematopoietic system physiology / MGI
- abnormal vasodilation / MGI
- abnormal blood vessel morphology / MGI
- abnormal immune system physiology / MGI
- altered susceptibility to infection / MGI
- abnormal inflammatory response / MGI
- decreased susceptibility to viral infection / MGI
- decreased susceptibility to bacterial infection / MGI
- increased susceptibility to bacterial infection / MGI
- abnormal blood cell morphology/development / MGI
- abnormal leukocyte physiology / MGI
- abnormal macrophage morphology / MGI
- abnormal macrophage physiology / MGI
- granulomatous inflammation / MGI
- increased heart rate / MGI
- decreased circulating triglyceride level / MGI
- dilated renal tubules / MGI
- decreased circulating insulin level / MGI
- decreased heart weight / MGI
- decreased systemic arterial blood pressure / MGI
- decreased hemoglobin content / MGI
- increased insulin sensitivity / MGI
- abnormal bone mineralization / MGI
- delayed wound healing / MGI
- abnormal leukocyte migration / MGI
- nephrocalcinosis / MGI
- nervous system phenotype / MGI
- abnormal physiological neovascularization / MGI
- impaired macrophage chemotaxis / MGI
- decreased macrophage cell number / MGI
- decreased lean body mass / MGI
- abnormal striatum morphology / MGI
- renal tubular necrosis / MGI
- decreased incidence of tumors by chemical induction / MGI
- increased hematopoietic stem cell number / MGI
- decreased susceptibility to experimental autoimmune uveoretinitis / MGI
- lung cysts / MGI
- abnormal vascular wound healing / MGI
- increased osteoclast cell number / MGI
- decreased osteoclast cell number / MGI
- decreased bone resorption / MGI
- abnormal osteoblast physiology / MGI
- increased lymphocyte cell number / MGI
- abnormal wound healing / MGI
- abnormal response to infection / MGI
- decreased acute inflammation / MGI
- decreased cardiac muscle contractility / MGI
- increased susceptibility to injury / MGI
- improved glucose tolerance / MGI
- decreased susceptibility to atherosclerosis / MGI
- renal/urinary system phenotype / MGI
- homeostasis/metabolism phenotype / MGI
- reproductive system phenotype / MGI
- skeleton phenotype / MGI
- increased macrophage cell number / MGI
- hyporesponsive to tactile stimuli / MGI
- increased circulating creatinine level / MGI
- decreased circulating glucose level / MGI
- increased blood urea nitrogen level / MGI
- decreased susceptibility to type IV hypersensitivity reaction / MGI
- increased lung weight / MGI
- calcified aortic valve / MGI
- decreased systemic arterial systolic blood pressure / MGI
- decreased urine sodium level / MGI
- decreased dendritic cell number / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-gamma secretion / MGI
- decreased circulating interleukin-6 level / MGI
- increased interleukin-10 secretion / MGI
- decreased interleukin-12 secretion / MGI
- increased interleukin-4 secretion / MGI
- abnormal chemokine level / MGI
- increased physiological sensitivity to xenobiotic / MGI
- decreased physiological sensitivity to xenobiotic / MGI
- decreased sensitivity to induced cell death / MGI
- increased neuron number / MGI
- increased trabecular bone thickness / MGI
- crystalluria / MGI
- increased sensitivity to induced morbidity/mortality / MGI
- decreased susceptibility to bacterial infection induced morbidity/mortality / MGI
- increased respiratory quotient / MGI
- abnormal macrophage chemotaxis / MGI
- mortality/aging / MGI
- decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
- decreased urine chloride ion level / MGI
- decreased fibroblast chemotaxis / MGI
Literature references
- Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7).;Wittig B M, Johansson B, Zöller M, Schwärzler C, Günthert U, ;2000;The Journal of experimental medicine;191;2053-64; 10859330
- The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.;Chabas D, Baranzini S E, Mitchell D, Bernard C C, Rittling S R, Denhardt D T, Sobel R A, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg J R, Steinman L, ;2001;Science (New York, N.Y.);294;1731-5; 11721059
- Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.;Rittling S R, Matsumoto H N, McKee M D, Nanci A, An X R, Novick K E, Kowalski A J, Noda M, Denhardt D T, ;1998;Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research;13;1101-11; 9661074
- Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.;Denhardt D T, Noda M, O'Regan A W, Pavlin D, Berman J S, ;2001;The Journal of clinical investigation;107;1055-61; 11342566